NCT01120249
Clinical Trial Information
Trial Number: NCT01120249 (ClinicalTrials.gov)
Disease Type:
- Kidney Neoplasm - Renal Cell Carcinoma
Trial Title:
EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study
Study ID:
S0931
Images are available?:
No
Is this a NCI-MATCH Trial?:
No
Datasets Linked to Trial
| Title | Description |
|---|---|
| NCT01120249-D2 | This dataset contains the results reported in The Lancet (Ryan et al., The Lancet, 2023). The toxicity dataset contains event-level information (one row per patient per adverse event experience on trial). NCT01120249-D1 contains baseline information and outcome data. |
| NCT01120249-D1 | This dataset contains the results reported in The Lancet (Ryan et al., The Lancet, 2023). The clinical dataset contains patient-level data (one row per patient), including, eligibility, evaluability, treatment, demographic, baseline information, and unblinding. It also contains assessment data. NCT01120249-D2 contains toxicity data. |
Accessibility | Disclaimer | FOIA | HHS Vulnerability Disclosure | Privacy & Security
U.S. Department of Health and Human Services | National Institutes of Health | National Cancer Institute | USA.gov
NIH…Turning Discovery Into Health®